The majority of two FDA advisory panels voted to modify or remove the prescribing restrictions on the type 2 diabetes drug rosiglitazone, based on the readjudicated results of a cardiovascular outcomes study, the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial. Meeting participants spoke with IMNG Medical Media about the panels' recommendations.
Video
FDA panels revisit rosiglitazone's cardiovascular safety
Publish date: June 13, 2013
Author(s):
Elizabeth Mechcatie